These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 12710864)

  • 1. Cardiovascular drug therapy in the elderly: theoretical and practical considerations.
    Williams BR; Kim J
    Drugs Aging; 2003; 20(6):445-63. PubMed ID: 12710864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular drug therapy in the elderly.
    Aronow WS; Frishman WH; Cheng-Lai A
    Cardiol Rev; 2007; 15(4):195-215. PubMed ID: 17575484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cardiovascular disease on pharmacokinetics.
    Rodighiero V
    Cardiovasc Drugs Ther; 1989 Oct; 3(5):711-30. PubMed ID: 2577313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450-mediated cardiovascular drug interactions.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1065-82. PubMed ID: 21810031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
    Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
    JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular pharmacotherapy in patients with Marfan syndrome.
    Yetman AT
    Am J Cardiovasc Drugs; 2007; 7(2):117-26. PubMed ID: 17503882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues in the perioperative management of the elderly patient with cardiovascular disease.
    Sear JW; Higham H
    Drugs Aging; 2002; 19(6):429-51. PubMed ID: 12149050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.
    Piepho RW; Fendler KJ
    Drugs Aging; 1991 May; 1(3):194-211. PubMed ID: 1686570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender, ethnicity, and genes in cardiovascular disease. Part 2: implications for pharmacotherapy.
    Schaefer BM; Caracciolo V; Frishman WH; Charney P
    Heart Dis; 2003; 5(3):202-14. PubMed ID: 12783634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex and gender differences in cardiovascular drug therapy.
    Seeland U; Regitz-Zagrosek V
    Handb Exp Pharmacol; 2012; (214):211-36. PubMed ID: 23027453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?
    Pourdjabbar A; Lapointe N; Rouleau JL
    Can J Cardiol; 2002 May; 18 Suppl A():7A-14A. PubMed ID: 12045788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of vasodilators. Part I.
    Kirsten R; Nelson K; Kirsten D; Heintz B
    Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes in parameters of coagulation system after treatment of chronic heart failure with β-adrenoblockers, angiotensin-converting enzyme inhibitors, calcium antagonists, diuretics, anticoagulants, antiagregants, cardiac glycosides, and physical exercise].
    Mongirdienė A
    Medicina (Kaunas); 2011; 47(4):238-43. PubMed ID: 21829057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of circadian rhythms on drug response in hypertension and coronary heart disease--from mice and man.
    Lemmer B
    Pharmacol Ther; 2006 Sep; 111(3):629-51. PubMed ID: 16480770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs].
    Noll G; Kaufmann U; Wenzel RR; Lüscher TF
    Schweiz Med Wochenschr; 1996 Feb; 126(5):164-76. PubMed ID: 8685687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular pharmacotherapeutic considerations in patients undergoing anesthesia.
    Wolf A; McGoldrick KE
    Cardiol Rev; 2011; 19(1):12-6. PubMed ID: 21135597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment after myocardial infarction].
    Beurrier D; Danchin N
    Presse Med; 1994 Feb; 23(8):380-4. PubMed ID: 7911570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.